You are here

Nat Commun DOI:10.1038/s41467-018-04356-9

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Publication TypeJournal Article
Year of Publication2018
AuthorsNg, SY, Yoshida, N, Christie, AL, Ghandi, M, Dharia, NV, Dempster, J, Murakami, M, Shigemori, K, Morrow, SN, Van Scoyk, A, Cordero, NA, Stevenson, KE, Puligandla, M, Haas, B, Lo, C, Meyers, R, Gao, G, Cherniack, A, Louissaint, A, Nardi, V, Thorner, AR, Long, H, Qiu, X, Morgan, EA, Dorfman, DM, Fiore, D, Jang, J, Epstein, AL, Dogan, A, Zhang, Y, Horwitz, SM, Jacobsen, ED, Santiago, S, Ren, J-G, Guerlavais, V, D Annis, A, Aivado, M, Saleh, MN, Mehta, A, Tsherniak, A, Root, D, Vazquez, F, Hahn, WC, Inghirami, G, Aster, JC, Weinstock, DM, Koch, R
JournalNat Commun
Date Published2018 05 22
KeywordsAnimals, Antineoplastic Agents, Cell Cycle Proteins, Depsipeptides, Drug Evaluation, Preclinical, Gene Expression Regulation, Neoplastic, Humans, Ikaros Transcription Factor, Imidazolines, Janus Kinase 2, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Mice, Nuclear Proteins, Peptides, Protein Binding, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-mdm2, Remission Induction, Signal Transduction, Tumor Suppressor Protein p53, Whole Exome Sequencing, Xenograft Model Antitumor Assays

T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are few preclinical models of TCLs, which has hampered the development of effective therapeutics. Here we establish and characterize preclinical models of TCL. We identify multiple vulnerabilities that are targetable with currently available agents (e.g., inhibitors of JAK2 or IKZF1) and demonstrate proof-of-principle for biomarker-driven therapies using patient-derived xenografts (PDXs). We show that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type TCLs. ALRN-6924, a stapled peptide that blocks interactions between p53 and both MDM2 and MDMX has potent in vitro activity and superior in vivo activity across 8 different PDX models compared to the standard-of-care agent romidepsin. ALRN-6924 induced a complete remission in a patient with TP53-wild-type angioimmunoblastic T-cell lymphoma, demonstrating the potential for rapid translation of discoveries from subtype-specific preclinical models.


Alternate JournalNat Commun
PubMed ID29789628
PubMed Central IDPMC5964252
Grant ListK23 CA184279 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
T32 CA009172 / CA / NCI NIH HHS / United States
T32 CA136432 / CA / NCI NIH HHS / United States